Latest News

Collaboration Agreement Seeks to engage AI to Transform Non-clinical Pathology Assessments in Drug Discovery and Development   DUBLIN, Ireland, April 23, 2024 – Deciphex, a Dublin-based digital pathology company,has entered into a Collaboration Agreement with Novartis […]

LEIDEN, The Netherlands – March 21, 2024 – Artica Therapeutics B.V. (Artica), a biotechnology company developing a pipeline of covalent small molecules for autoimmune and inflammatory disorders, today announced that industry veteran Piet Wigerinck PhD is […]

19 March 2024 – DUBLIN– We are pleased to announce that our portfolio company Fusion Pharmaceuticals Inc., (FUSN), is to be acquired for up to $2.4 billion by AstraZeneca. Fusion, is a clinical-stage biopharmaceutical company, headquartered […]

Sibylla Biotech Enters a Strategic Drug Discovery Collaboration with Ono Pharmaceutical in Central Nervous System Disorders   Milan, Italy, March 14, 2024 – Sibylla Biotech announced today a drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (TSE: […]

Naperville, Illinois, USA.  5 March 2024.  Endotronix, Inc., a privately held company dedicated to advancing the treatment of heart failure (HF) at the intersection of digital health and medtech, presented 6-month results from its PROACTIVE-HF pivotal […]    

Seroba Announces Above Target Final Close of its Fund IV at €123M ($134M). • Seroba, a European life sciences venture capital firm headquartered in Dublin, with offices in Paris and Milan, announces the final close of […]

U.S.-Ireland Specialty Pharmaceutical Company’s ready-to-dilute form of a drug for the treatment of adenocarcinoma of the breast or ovary January 9, 2024 – CAMBRIDGE, Mass. – Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that […]

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top